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The aim of the study was to draw a comparison between the characteristics of infective endocarditis (IE) in patients with cancer and
those of IE in noncancer patients.
Patients with IE, according to themodified Duke criteria, were prospectively included in the GAMES registry between January 2008
and February 2014 in 30 hospitals. Patients with active cancer were compared with noncancer patients.
During the study period, 161 episodes of IE fulfilled the inclusion criteria. We studied 2 populations: patients whose cancer was
diagnosed before IE (73.9%) and those whose cancer and IE were diagnosed simultaneously (26.1%). The latter more frequently had
community-acquired IE (67.5% vs 26.4%, P< .01), severe sepsis (28.6% vs 11.1%, P= .013), and IE caused by gastrointestinal
streptococci (42.9% vs 16.8%, P< .01). However, catheter source (7.1% vs 29.4%, P= .003), invasive procedures (26.2% vs
44.5%, P= .044), and immunosuppressants (9.5% vs 35.6%, P= .002) were less frequent.
When compared with noncancer patients, patients with cancer were more often male (75.2% vs 67.7%, P= .049), with a higher
comorbidity index (7 vs 4). In addition, IE wasmore often nosocomial (48.7% vs 29%) and originated in catheters (23.6% vs 6.2%) (all
P< .01). Prosthetic endocarditis (21.7% vs 30.3%, P= .022) and surgery when indicated (24.2% vs 46.5%, P< .01) were less
common. In-hospital mortality (34.8% vs 25.8%, P= .012) and 1-year mortality (47.8% vs 30.9%, P< .01) were higher in cancer
patients, although 30-day mortality was not (24.8% vs 19.3%, P= .087).
A significant proportion of cases of IE (5.6%) were recorded in cancer patients, mainly as a consequence of medical interventions.
IE may be a harbinger of occult cancer, particularly that of gastrointestinal or urinary origin.
Abbreviations: GAMES = Grupos de Ayuda al Manejo de la Endocarditis (Spanish Collaboration on Endocarditis), ICE =
International Collaboration on Endocarditis, IE = infective endocarditis, IQR = interquartile range, OR = odds ratio.
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The importance of active cancer as an underlying disease in
patients with infective endocarditis (IE) has not been specifically
addressed, although neoplasms are common in patients with
IE.[1]
The reciprocal and negative influence of cancer and IE on the
management of both conditions is easy to envision but not
frequently addressed. Potential higher mortality has been
suggested in patients with cancer.[2] Some studies report an
association between intra-abdominal cancer and endocarditis,[3]
whereas others report a high incidence of nosocomial IE caused
by staphylocci.[2] However, specific characteristics and prognos-
tic factors have not been analyzed. Studies describing IE in
patients with cancer or vice versa are subject to limitations: they
analyze single-center cohorts,[2] do not draw comparisons with
a population without cancer,[4] focus only on nonbacterial
thrombotic endocarditis[5] or endocarditis associated with
specific kinds of cancer,[3] and report the association in specific
population subsets.[6]
Our objective was to describe the clinical characteristics and
prognosis of IE in cancer patients in a large, multicenter cohort of
patients with IE by comparing themwith those of IE in noncancer
patients.We assessed 2 populations: patients in whom cancer had
been diagnosed before IE and patients in whom IE was diagnosed
before cancer, thus pointing to cancer as a potential portal of
entry for IE.2. Materials and methods
2.1. Setting
In 2008, in association with the International Collaboration on
Endocarditis (ICE),[1] a national cooperative endocarditis study
group, Grupo de Apoyo al Manejo de la Endocarditis Infecciosa
en España (GAMES [the Spanish Collaboration on Endocardi-
tis]), was created in Spain with the objective of improving the care
of IE patients and conducting research. GAMES is a prospective
registry managed by a multicenter multidisciplinary group
dedicated to improving the management of IE.[7]2.2. Patients
Consecutive patients with IE were prospectively included in the
GAMES registry between January 2008 and February 2014
in 30 Spanish hospitals. Multidisciplinary teams completed a
standardized case report form. Patients were followed for 1 year.
Patients with and without active cancer were compared.2.3. Definitions
We defined active cancer as hematological neoplasm or solid
tumors diagnosed<5 years before IE or any cancer managedwith
active cancer therapy at admission for IE. In the case of
nonadvanced cancer, only those diagnosed <6 months before IE
were considered active.[8] Cancer was stratified according to the
stage of the disease at diagnosis of IE. Stage was considered
advanced when the tumor was locally advanced or metastatic
(solid tumors), or when the patient had received reinduction
therapy, or a recurrence had been diagnosed (hematological
cancer). We analyzed 2 subsets: patients with a diagnosis of
cancer before the diagnosis of IE (established cancer) and patients
in whom cancer was diagnosed simultaneously with IE (same
admission) or subsequently (newly discovered cancer).2
IE was defined according to the modified Duke criteria.
Site of acquisition of IE was defined following ICE
recommendations.[10] In brief, community-acquired IE was
defined as IE diagnosed within the first 48 hours of admission
in a patient who did not fulfill the criteria for nosocomial or
health care-associated infection. Nosocomial IE was defined as IE
in a patient who had been hospitalized for >48hours before the
onset of signs or symptoms consistent with IE. Health care-
associated IE was diagnosed within 48hours of admission of an
outpatient with any of the following criteria [11]: intravenous
therapy, wound care, or specialized nursing care at home within
the 30 days before the onset of IE; attendance at a hospital or
hemodialysis clinic or receipt of intravenous chemotherapy
within the 30 days before the onset of IE; hospitalization in an
acute care hospital for ≥2 days during the 90 days before the
onset of IE; or residence in a nursing home or long-term care
facility.
The source of endocarditis was considered to be the alleged
source when the same microorganism was isolated in blood
cultures and the potential source (e.g., catheter), when there was a
clinical source compatible with the microorganism (e.g.,
Enterococcus and evidence of urinary infection in a patient with
a permanent urinary catheter) and/or when an invasive
intervention was performed before the diagnosis of IE that could
be temporally and microbiologically related to the etiology of the
endocarditis.
An implantable cardiac device was defined as a permanent
pacemaker and/or cardioverter-defibrillator.
Prosthetic valve IE was defined as an endovascular
infection affecting a prosthetic valve or reconstructed native
heart valve, irrespective of whether the prosthesis was a
mechanical prosthesis and/or bioprosthetic xenograft (stented
or unstented) and/or repaired native valve with implantation of
an annular ring.
The EuroSCORE was used to assess operative risk in heart
surgery.[12,13] We used the age-adjusted Charlson comorbidity
index to categorize comorbidities.[14]
All patients were evaluated by cardiac surgeons following
international indications to determine the need for surgery.[15]
The final decision on surgery was made in agreement with the
multidisciplinary endocarditis team at each center, including the
oncologist.
Both in-hospital mortality (overall mortality rate during the
hospital stay) and 30-day mortality (considered likely related to
the infection[16]) were analyzed. Long-termmortality was defined
as mortality at 1 year.2.4. Data analysis
Patients with active cancer at admission for IE were analyzed and
compared with the rest of the patients in the database.
Among patients with cancer, those with a previous diagnosis of
cancer were compared with those who had a simultaneous
diagnosis of IE and cancer (same month).
Quantitative variables were expressed as mean and standard
deviation or as median and interquartile range (IQR), as
appropriate; qualitative variables were expressed as frequency
and percentage. Continuous variables were compared using the
t test, and categorical variables were compared using the x2 test or
Fisher exact test when the x2 test was not appropriate. Adjusted
odds ratios (ORs) were computed using logistic regression
analysis. Stepwise logistic regression analysis was performed
including variables with a P < .1 in the univariate analysis. All
Fernández-Cruz et al. Medicine (2017) 96:38 www.md-journal.comstatistical analyses were performed using PASW Statistics for
Windows, version 18.0 (SPSS Inc, Chicago, IL).2.5. Ethics
The study and the common case report form were approved by
the local and national institutional review boards and ethics
committees (E.C. 18/07).3. Results
3.1. Incidence and etiology of IE in cancer patients
During the 6-year study period, 161 cases in 160 patients from 30
Spanish hospitals fulfilled the inclusion criteria (5.6% of all cases
of IE diagnosed during the same period-2888 episodes of
endocarditis). The characteristics of patients with and without
cancer are summarized in Table 1.
The etiology of IE in cancer patients is shown in Figure 1. A
significant association was found between colon cancer and
streptococcal etiology (32.7% vs 18.3%, P= .048). We failed to
find any further association between other etiologies and other
kinds of cancer.
Of note, an etiological diagnosis for IE was not attained in 14
cases (8.7%); therefore, it was not possible to exclude
nonbacterial thrombotic endocarditis. Significant differences
between cases with and without a microbial etiology are
summarized in Table 2. Cases without an etiologic diagnosis
had significantly more embolisms and higher in-hospital
mortality and were found more often in patients without a
prosthetic valve.3.2. Characteristics of IE according to the time of cancer
diagnosis
The underlying neoplasm was hematological in 19.4% and a
solid tumor in 80.6% (Fig. 2). The most common malignant
neoplasm was colon cancer (33.5%), followed by prostate cancer
(9.7%), lymphoma (8.4%), and urothelial tumors (8.4%).
We identified 2 different populations: patients with a cancer
diagnosis before IE (established cancer) (119, 73.9%) and
patients in whom IE was diagnosed simultaneously with cancer
(same admission) or subsequently (newly discovered cancer) (42,
26.1%).
In patients with established cancer, the median time from
cancer to IE was 257 days (IQR 67–809). Cancer was at an
advanced stage in 56.1%. At diagnosis of IE, only 1 patient was
neutropenic, although 42 (25.6%) had recently received
chemotherapy.
Patients with established and newly discovered cancer were
compared (Table 3). Cases where endocarditis was a harbinger of
cancer were more likely to be community-acquired, were less
frequently treated with immunosuppressors, presented with
severe sepsis, and were caused by gastrointestinal streptococci.
On the contrary, catheter source and invasive procedures before
the IE episode were less frequent. There were no differences in
surgical management or outcome.3.3. Comparison between patients with and without
cancer
When we compared patients with and without cancer (Table 1),
cancer patients weremore oftenmale (75.2%vs 67.7%, P= .049)3
and significantly older (median age 70 [IQR 63–77] vs 68 [IQR
56–77], P= .02) and had a higher age-adjusted Charlson
comorbidity index (mean 7 vs 4, P< .01).
IE was more often nosocomial in cancer patients (48.7% vs
29.9%, P= .01). In 23.6% of cases, a central venous catheter was
purportedly the source of IE compared with only 6.2% in
noncancer patients (P= .01). Genitourinary or intestinal sources
of endocarditis were also significantly more frequent in cancer
patients.
Clinical presentation was unspecific, although the diagnostic
criteria were less often definite than in noncancer patients (73.9%
vs 80.6%, P= .04). Prosthetic IE was less frequent in patients
with cancer (21.7% vs 30.3%, P= .02). Interestingly, 4 cases had
mural IE (among 16 cases of nonvalvular IE).
Candida and polymicrobial IE were significantly more frequent
among cancer patients (4.3% vs 1.6%, P= .009; and 5% vs
1.7%, P= .003, respectively) (Fig. 2). Persistent bacteremia was
more common in cancer patients (16.9% vs 10.9%, P= .009).
Surgery, although indicated, was performed less often in cancer
patients (24.2% vs 46.5%, P= .01). The reasons for not
performing surgery were death before surgery (18.4%), poor
prognosis after surgery (7.9%), poor prognosis of underlying
disease (55.3%), hemodynamic instability (5.3%), and cirrhosis,
stroke, or patient/surgeon refusal (2.6% each). The reasons for
not operating were unknown in 2 cases.
There were no differences in 30-day mortality (24.8% vs
19.3%, P= .09), although in-hospital mortality was higher in
cancer patients (34.8% vs 25.8%, P= .01). One-year mortality
was significantly higher in cancer patients (47.8% vs 30.9%,
P= .01) (Fig. 3).
The multivariate analysis (Table 4) confirmed that IE in cancer
patients more often affected men, with a higher age-adjusted
comorbidity index, and was more often hospital-acquired and
originated in catheters. Prosthetic valve endocarditis was less
frequent, and cancer patients underwent surgery significantly less
frequently when surgery was indicated.3.4. Risk factors for mortality in cancer patients
Among patients with active cancer, Staphylococcus aureus IE,
new heart failure, and nonsurgical therapy were independent
prognostic factors for 30-day mortality. No cancer-related
factors were associated with 30-day mortality (Table 5).
In-hospital mortality in cancer patients was independently
associated with a higher age-adjusted Charlson comorbidity
index and development of heart failure, whereas a streptococcal
etiology was a protective factor (Table 6). Among patients who
died during admission, death was from endocarditis in 41% of
cases, cancer in 10.7%, other causes in 17.8%, and unknown
origin in 30.4%.
Wewere not able to identify independent risk factors for 1-year
mortality.
In patients who underwent surgery, mortality at discharge, 30
days, and 1 year was similar for cancer and noncancer patients,
and lower than in nonoperated patients for whom surgery was
indicated, independently of cancer stage (Table 7).4. Discussion
Our study shows that a significant proportion of IE patients
(5.6%) have underlying active cancer and that IE may be a
harbinger or a consequence of cancer. Endocarditis behaves
differently in cancer patients, although risk factors for 30-day
Table 1
Characteristics of infective endocarditis in patients with and without cancer.
Variable (%) No cancer (N=2727) Cancer (N=161) P
∗
Sex (male) 1842 (67.7) 121 (75.2) .049
Age (median, IQR) 68 (56–77) 70 (63–77) .02
Days of symptoms before diagnosis (median, IQR) 20 (10–43) 11 (9–21) .01
Underlying conditions
Age-adjusted Charlson comorbidity score (mean, SD) 4 (3–6) 7 (5–8) .01
Chronic heart failure 885 (32.6) 28 (17.4) .01
Dyslipemia 930 (34.3) 42 (26.4) .04
Connective tissue disease 85 (3.1) 1 (0.6) .07
Immunosuppressive therapy 131 (4.8) 46 (28.8) .01
Patients with cardiac devices 493 (18.1) 20 (12.4) .17
Patients with previous valve surgery or prosthesis 946 (34.8) 44 (27.3) .15
Acquisition
Community-acquired 1610 (61.6) 56 (37.6) .01
Hospital-acquired 782 (29.9) 73 (48.7) .01
Health care-related 220 (8.4) 21 (14.1) .02
Source of endocarditis 1251 (45.9) 108 (67.1) .01
Catheter 169 (6.2) 38 (23.6) .01
Odontogenic 163 (6.0) 5 (3.1) .13
Respiratory 28 (1.0) 4 (2.5) .09
Genitourinary 128 (4.7) 17 (10.6) .001
Gastrointestinal 170 (6.2) 24 (14.9) .01
Skin and soft tissue 182 (6.7) 10 (6.2) .82
Diagnosis
Definite 2188 (80.6) 119 (73.9) .04
Possible 527 (19.4) 42 (26.1) .04
Affected valve
Aortic 1331 (48.8) 71 (44.1) .25
Mitral 1170 (42.9) 72 (44.7) .65
Tricuspid 143 (5.2) 10 (6.2) .59
Pulmonary 43 (1.6) 2 (1.2) .54
Prosthetic valve 825 (30.3) 35 (21.7) .02
Native valve 1668 (61.2) 106 (65.8) .24
Nonvalvular (pacemaker wire or other) 379 (13.9) 16 (9.9) .16
Etiology
Coagulase negative staphylocci 476 (17.5) 26 (16.1) .67
Staphylococcus aureus 606 (22.3) 38 (23.6) .68
Enterococcus 378 (13.9) 23 (14.3) .88
Streptococcus 694 (25.5) 38 (23.6) .60
Gram-negative bacilli 110 (4.0) 5 (3.1) .56
Anaerobes 30 (1.1) 1 (0.6) .57
Candida 43 (1.6) 7 (4.3) .009
Other fungi 10 (0.4) 1 (0.6) .61
Other etiologies 83 (3.0) 0 (0) .03
Polymicrobial 46 (1.7) 8 (5) .003
Unknown 251 (9.2) 14 (8.7) .83
Outcome
Embolisms 943 (34.6) 46 (28.6) .15
Intracardiac complication 773 (28.5) 46 (28.8) .99
Perforation or tear 352 (12.9) 17 (10.5) .46
Pseudoaneurysm 138 (5.0) 6 (3.7) .57
Abscess 384 (14.1) 28 (17.4) .29
Intracardiac fistula 69 (2.5) 4 (2.4) .82
Heart failure 1099 (40.6) 50 (31.3) .06
New conduction abnormality 226 (8.4) 16 (10.0) .41
Severe sepsis 420 (15.4) 25 (15.5) .94
Septic shock 312 (11.4) 21 (13.0) .47
Persistent bacteremia 295 (10.9) 27 (16.9) .009
Surgery indicated 1784 (66.0) 78 (48.8) .01
Cardiovascular surgery 1268 (46.5) 39 (24.2) .01
30-d mortality 527 (19.3) 40 (24.8) .09
In-hospital mortality 703 (25.8) 56 (34.8) .01
1-year mortality 844 (30.9) 77 (47.8) .01
IQR= interquartile range, SD= standard deviation.
∗
Statistically significant P values are highlighted (bold).
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Figure 1. Etiology of infective endocarditis in patients with and without cancer. CNS = coagulase-negative staphylococci.
Table 2







Prosthesis (%) 29.9 0 .01
Embolisms (%) 27.2 42.9 .04
Vascular CNS event (%) 9.6 35.7 .01
Lung cancer (%) 4.1 21.4 .03
Low intestinal cancer (%) 34.7 7.1 .04
In-hospital mortality (%) 31.3 71.4 .006
1-year mortality (%) 41.5 85.7 .002
CNS = central nervous system.
No significant differences were found for 30-day mortality, surgery, catheters, length of stay, age, or
time from cancer diagnosis.
Fernández-Cruz et al. Medicine (2017) 96:38 www.md-journal.commortality (which we consider attributable mortality) are similar
to those for the general population of patients with endocardi-
tis.[7] Long-term prognosis is related to the underlying disease.
Data on the prevalence of cancer among patients with IE are
scarce in the literature, and it is generally not determined whether
cancer is active or not when IE is diagnosed.[1] In our series, we
only included patients with active cancer, thus possibly
accounting for the somewhat lower prevalence in the present
study (5.6% vs 8% elsewhere[1]).
We identified 2 different populations in cancer patients with
IE: one with a previous diagnosis of cancer, in which IE is aFigure 2. Under
5
consequence of cancer management, and another, in which IE is
diagnosed after the diagnosis of cancer. There are opportunities
both for early diagnosis of cancer and for prevention of
endocarditis.
The association between colon cancer and IE is well
known[3,6,17,18]; however, in our series, a high risk of IE was
also present for lymphoma, prostate cancer, and genitourinary
cancer. In many cases, IE occurs concurrently with, and even
leads to, a diagnosis of cancer (42; 26% cases).[19] The only
association we were able to find between the etiology of IE and
the underlying tumor was streptococcal endocarditis in patients
with colon cancer. An association between Streptococcus bovis
(S. gallolyticus subsp gallolyticus) and colon cancer has been
thoroughly described,[18] and several mechanisms have been
proposed.[17] Although an association between other types of
streptococcal endocarditis and colon cancer has been reported
(Kestler et al, in press), this is not as strong as in the case of S.
gallolyticus. Some authors suggest that the risk of being
diagnosed with cancer is higher in patients with IE than in
those without IE, in particular during the first 3 months of follow-
up, although this period can be as long as 4 years.[19,20] This is an
important issue for early diagnosis of cancer, particularly when
made based on colonoscopy in patients with streptococcal
endocarditis. The current European guidelines[15] recommend
ruling out cancer in cases of IE caused by S. bovis (gallolyticus).
The increasing use of PET/CT in the extension study can help
diagnose occult cancer in patients with IE.[7]lying cancer.
Table 3
Characteristics of infective endocarditis according to when cancer was diagnosed.
Variable (%) Newly discovered cancer (N=42) Established cancer (N=119) P
Sex (male) 34 (81%) 87 (73.1%) .41
Age (median, IQR) 69.5 (62.8–76.3) 70 (63–77) .98
Underlying conditions
Age-adjusted Charlson comorbidity score (mean, SD) 6 (4–8.25) 7 (5–8) .84
Chronic heart failure 9 (21.4%) 19 (16%) .48
Dyslipemia 14 (34.1%) 28 (23.7%) .42
Benign colonic pathology 6 (17.6%) 13 (14.6%) .78
Immunosuppressive therapy 4 (9.5%) 42 (35.6%) .002
Patients with cardiac devices 6 (14.3%) 14 (11.8%) .79
Patients with previous valve surgery or prosthesis 8 (19.0%) 36 (30.3%) .23
Acquisition
Community-acquired 27 (67.5%) 29 (26.4%) <.001
Hospital-acquired 11 (27.5%) 62 (56.4%) .003
Health care–related 2 (5%) 19 (17.3%) .06
Source of endocarditis
Catheter 3 (7.1%) 35 (29.4%) .003
Odontogenic 2 (4.9%) 3 (2.5%) .60
Respiratory 1 (2.4%) 3 (2.5%) >.99
Genitourinary 2 (4.9%) 15 (12.6%) .24
Gastrointestinal 11 (26.8%) 13 (10.9%) .02
Skin and soft tissue 4 (9.8%) 6 (5.1%) .28
Invasive procedure 11 (26.2%) 53 (44.5%) .04
Diagnosis
Definite 28 (66.7%) 91 (76.5%) .23
Possible 14 (33.3%) 28 (23.5%) .23
Affected valve
Aortic 15 (35.7%) 56 (47.1%) .21
Mitral 21 (50%) 51 (42.9%) .47
Tricuspid 2 (4.8%) 8 (6.7%) >.99
Pulmonary 1 (2.4%) 1 (0.8%) .46
Prosthetic valve 5 (11.9%) 30 (25.2%) .08
Native valve 31 (73.8%) 75 (63.0%) .26
Nonvalvular (pacemaker wire or other) 6 (14.3%) 14 (11.8%) .79
Etiology
Coagulase negative staphylococci 3 (7.1%) 23 (19.3%) .09
Staphylococcus aureus 8 (19.0%) 30 (25.2%) .53
Enterococcus 3 (7.1%) 20 (16.8%) .20
Streptococcus 18 (42.9%) 20 (16.8%) .001
Gram-negative bacilli 1 (2.4%) 4 (3.4%) >.99
Anaerobes 1 (2.4%) 0 (0%) .26
Candida 0 (0%) 7 (5.9%) .19
Other fungi 0 (0%) 1 (0.8%) >.99
Polymicrobial 2 (4.8%) 6 (5%) >.99
Unknown 6 (14.3%) 8 (6.7%) .20
Outcome
Embolisms 16 (38.1%) 30 (25.2%) .19
Intracardiac complication 10 (21.7%) 36 (30.5%) .62
Perforation or tear 5 (12.2%) 12 (10.3%) .79
Pseudoaneurysm 1 (2.4%) 5 (4.3%) .73
Abscess 4 (9.8%) 24 (20.5%) .24
Intracardiac fistula 0 (0%) 4 (3.4%) .41
Heart failure 15 (35.7%) 35 (29.7%) .56
New conduction abnormality 4 (9.5%) 12 (10.2%) .65
Severe sepsis 12 (28.6%) 13 (11.1%) .01
Septic shock 9 (21.4%) 12 (10.3%) .10
Persistent bacteremia 4 (9.5%) 23 (19.5%) .33
Surgery indicated 22 (52.4%) 56 (47.5%) .64
EuroSCORE 10 (7–12.5) 11 (8–14) .37
Cardiovascular surgery 11 (26.2%) 28 (23.5%) .83
30-d mortality 9 (21.4%) 31 (26.1%) .68
In-hospital mortality 12 (28.6%) 44 (37%) .35
1-year mortality 19 (45.2%) 54 (45.4%) >.99
IQR= interquartile range, SD= standard deviation.
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Figure 3. One-year survival in patients with and without cancer.
Table 5
Risk factors for 30-day mortality in cancer patients with infective
endocarditis.
Variable OR 95% CI P
Staphylococcus aureus infection 11.590 1.757–76.457 .01
New heart failure 9.610 1.580–58.447 .01
Surgery 0.143 0.021–0.982 .048
CI = confidence interval, OR = odds ratio.
Fernández-Cruz et al. Medicine (2017) 96:38 www.md-journal.comIn other cases, endocarditis is diagnosed after cancer and
application of its diagnostic and therapeutic measures. Previous
cancer facilitates IE by means of associated thrombotic
phenomena in cardiac valves that favor bacterial colonization
or as a consequence of medical management (e.g., catheter-
associated disease).
Nonbacterial thrombotic endocarditis is also found in cancer
patients. Yusuf et al[4] reported a 42% frequency of culture-
negative endocarditis in a retrospective series of consecutive
cancer patients. Classically, embolisms are more frequent in
nonbacterial thrombotic endocarditis, which occurs more
frequently in patients with lung, pancreas, and gastric cancer
and healthy valves.[21,22] In our series, it was not possible to reach
a microbiological diagnosis in 8.7% of cases, and we cannot rule
out the possibility that these cases involved nonbacterial
thrombotic endocarditis. Consistent with this finding, patients
with no known etiology had significantly more native valve
endocarditis, more embolisms, and higher long-term mortality. It
is important to bear in mind the possibility of noninfectious
endocarditis, which needs different management strategies.[21]
Hospital and health care-related acquisition were significantly
more frequent among patients with cancer, probably as a result of
the use of invasive techniques and devices, such as catheters.[23]
Long-term catheters are necessary in cancer patients, and
although the risk of infection in totally implantable catheters
is lower than in other catheters, these stay in place for longerTable 4
Independent differential factors for infective endocarditis (cancer
vs noncancer).
Variable OR 95% CI P
Sex (male) 1.61 1.08–2.4 .02
Surgery 0.454 0.301–0.684 .01
Nosocomial infection 1.75 1.21–2.53 .03
Age-adjusted Charlson comorbidity index >5 2.9 2.01–4.20 .01
Central catheter as a source 3.28 2.10–5.13 .01
Prosthetic endocarditis 0.608 0.398–0.930 .02
CI = confidence interval, OR = odds ratio.
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periods of time and are eventually responsible for a considerable
number of infections.[24] In a retrospective series of endocarditis
in patients with cancer, 60% of those with culture-positive
endocarditis had a central venous catheter.[4] In our series, the
catheter was purportedly the source of endocarditis in 23.6%.
Preventive measures have successfully prevented catheter-related
bloodstream infections in other settings.[25] As suggested by
Chu,[26] appropriate management of catheter-related bacteremia
is essential for source control in endocarditis. Both prevention
and management of catheter-related bacteremia are necessary to
prevent the development of endocarditis in cancer patients.
Programs specifically addressing long-term catheters are essen-
tial.
Interestingly, we found 4 cases of mural endocarditis (all right-
sided). It is possible that chemotherapy administered through
central venous catheters irritates the atrial wall and favors the
development of atrial endocarditis. Other authors have described
an association between thrombotic complications and catheter-
related bloodstream infections in long-term catheters.[27] Non-
valvular endocarditis is characteristically associated with central
catheters.[27–30]
Risk factors for 30-day mortality were similar to those of the
general population and were all noncancer-related factors,
whereas in-hospital mortality was also related to underlying
disease and comorbidity. Cancer was a risk factor for 1-year
mortality after IE, although not for short-term mortality, as
previously reported by our group.[7]
Surgery is rarely offered because of concern over major
postoperative complications and deterioration of an already
compromised health status. Whether endocarditis affects cancer
mortality[2,6] or does not affect it[3] remains a controversial issue.
In our series, there were no differences in postoperative mortality
between patients with and without cancer who had undergone
surgery. When evaluating a particular patient’s prognosis, we
need to bear inmind that short-term prognosis is similar to that of
any other patient with endocarditis, and in cases with a favorable
cancer prognosis and no other comorbidity, intensive manage-
ment and surgical therapy should be considered.
Our series may not represent the situation of IE in countries
where levels of health care differ from those of Spain, which has a
universal public health system.Table 6
Risk factors for in-hospital mortality in cancer patients with
infective endocarditis.
Variable OR 95% CI P
Streptococcus infection 0.12 0.04–0.39 <.001
New heart failure 4.885 2.226–10.718 <.001
Age-adjusted Charlson comorbidity index 1.172 1.014–1.356 .03
CI = confidence interval, OR = odds ratio.
Table 7
Mortality associated with surgery for infective endocarditis in patients with and without cancer according to stage.
No cancer Nonadvanced cancer Advanced cancer
30-d mortality Total (N=2727) Dead (527, 19.3%) P Total (N=56) Dead (13, 23.2%) P Total (N = 87) Dead (22, 25.3%) P
Surgery not indicated 788 (28.9) 72 (9.1) >.99 29 (51.8) 4 (11.4%) >.99 36 (41.4) 5 (11.9%) >.09
Surgery indicated and performed 1234 (45.3) 180 (14.6) >.99 9 (16.1) 1 (11.1%) >.99 23 (26.4) 3 (13%) >.99
Surgery indicated and not performed 549 (20.1) 237 (42.9) .05
∗
12 (21.4) 8 (66.7%) >.99 21 (24.1) 14 (66.7) >.99
Missing 156 (5.7) 38 (24.5) 6 (10.7) 7 (8.0) 0 (0%)
No cancer (N=2727) Nonadvanced cancer Advanced cancer
In-hospital mortality Total Dead (703, 25.7%) P Total (56) Dead (18, 32.1%) P Total (N = 87) Dead (32, 36.8%) P
Surgery not indicated 788 (28.9) 99 (12.5) >.99 29 (51.8) 6 (17.1%) >.99 36 (41.4) 6 (14.3%) >.99
Surgery indicated and performed 1234 (45.3) 265 (21.5) >.99 9 (16.1) 3 (33.3%) >.99 23 (26.4) 8 (34.8%) >.99
Surgery indicated and not performed 549 (20.1) 292 (52.9) .02
∗
12 (21.4) 9 (75.0%) .69 21 (24.1) 17 (81.0%) .69
Missing 156 (5.7) 47 (30.3) 6 (10.7) 7 (8.0) 1 (100%)
No cancer Nonadvanced cancer Advanced cancer
One-year mortality Total (N=2727) Dead (844, 30.9%) P Total (N=56) Dead (26, 46.4%) P Total (N = 87) Dead (43, 49.4%) P
Surgery not indicated 788 (28.9) 154 (19.5) >.99 29 (51.8) 11 (37.9) .03† 36 (41.4) 12 (33.3) >.99
Surgery indicated and performed 1234 (45.3) 312 (25.2) >.99 9 (16.1) 3 (33.3) >.99 23 (26.4) 10 (43.4) >.99
Surgery indicated and not performed 549 (20.1) 323 (58.8) >.99 12 (21.4) 10 (83.3) >.99 21 (24.1) 18 (85.7) .03
∗
Missing 156 (5.7) 55 (35.2) >.99 6 (10.7) 2 (33.3) >.99 7 (8.0) 3 (42.8) >.99
∗
Statistically significant difference between no cancer and advanced cancer patients.
† Statistically significant difference between no cancer and nonadvanced cancer patients.
Fernández-Cruz et al. Medicine (2017) 96:38 MedicineIn conclusion, a significant proportion of cases of IE (5.6%)
occur in cancer patients, mainly as a consequence of medical
interventions in established cancers. IE should prompt a search
for occult cancer, particularly in the gastrointestinal or urinary
tract. Our results will facilitate informed clinical decisions in
patients with IE and active cancer, thus enabling adequate
preventive measures to be established.
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